Osimertinib (AZD9291)

For research use only. Not for use in humans.

製品コードS7297 別名：Mereletinib

CAS No. 1421373-65-0

Osimertinib (AZD9291, Mereletinib) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

サイズ

価格(税別)

5mg	JPY 18100
10mg	JPY 24400
100mg	JPY 118200

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297|電子メール：[email protected]|よく尋ねられる質問

文献中Selleckの製品使用例(253)

製品安全説明書

EGFR阻害剤の選択性比較

生物活性

製品説明

特性

Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.

ターゲット

L858R/T790M EGFR ^[1] (LoVo cells)	Exon 19 deletion EGFR ^[1] (LoVo cells)	WT EGFR ^[1] (LoVo cells)
11.44 nM	12.92 nM	493.8 nM

体外試験

AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. ^[2]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PC-9/BRc1	M1vmbmZ2dmO2aX;uJGF{e2G7	MXq1NEBvVQ>?	M{LrZVI1KGh?	NVHrNmlnTE2VTx?=	MUPpcoR2[2W\|IHX4dJJme3Orb36gc4YhfGinIIDyc4Fxd3C2b4TpZ{BDS0xvMjDmZY1qdHlibXXtZoVzKEKLTR?=	M3q1SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N\|I2Lz5{NUS3O\|MzPTxxYU6=
PC-9/ERc1	M{\EdmZ2dmO2aX;uJGF{e2G7	M1G3NlUxKG6P	NVLBPHhUOjRiaB?=	NGq3OIJFVVOR	MlXlbY5lfWOnczDlfJBz\XO\|aX;uJI9nKHSqZTDwdo9ieG:ydH;0bYMhSkOOLUKg[oFucWy7IH3lcYJmeiCESV2=	NIn3fVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS3O\|MzPSd-MkW0O\|c{OjV:L3G+
VP-2	M2fLWGZ2dmO2aX;uJGF{e2G7	MUO1NEBvVQ>?	NVm4WYgxOjRiaB?=	NUP5dGFuTE2VTx?=	NX\xO3V3cW6mdXPld{BmgHC{ZYPzbY9vKG:oIITo[UBxem:jcH;weI91cWNiQlPMMVIh\mGvaXz5JI1mdWKncjDCTW0>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
PC-9/BRc1	NWnES3dqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEmxfIE2OCCwTR?=	M1S2dlExKGR?	NWDhfHRXTE2VTx?=	MUDpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHzvcocufGW{bTCoNVAu\GG7KTDndo94fGhiaX7obYJqfGmxbjDhd5NigXN?	NYTDUGxORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O\|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC-9/ERc1	M4rFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYm4U\|ZXPTBibl2=	NX62VmVuOTBiZB?=	MV7EUXNQ	Mm\kbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDsc45oNXSncn2gLFExNWSjeTmg[5Jwf3SqIHnubIljcXSrb36gZZN{[Xm\|	MmG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N\|I2RC:jPh?=
VP-2	MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXm1NEBvVQ>?	M3TrXFExKGR?	NHjzT2NFVVOR	MmT4bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDsc45oNXSncn2gLFExNWSjeTmg[5Jwf3SqIHnubIljcXSrb36gZZN{[Xm\|	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
PC9 GR4	M2XPU2Z2dmO2aX;uJGF{e2G7	M33sWFAuOTBizszN	NXv0epp2PzJiaB?=		MYrpcohq[mm2c9MgSWdHWiCyaH;zdIhwenmuYYTpc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7nxsA>	MmL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NEi2N\|MoRjJ3OUS4OlM{RC:jPh?=
PC9	Mlj6SpVv[3Srb36gRZN{[Xl?	MYWwMVExKM7:TR?=	NUK4PIxmPzJiaB?=		NIKyRpNqdmirYnn0d{BYXCCHR1\SJIF1KGyxdzDjc45k\W62cnH0bY9vew>?	NFzG[Y49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0PFY{Oyd-MkW5OFg3OzN:L3G+
PC9 GR4	MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LhcFAuOTBizszN	NGm3cFM4OiCq		Mk\zbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:\|ZTDk[ZBmdmSnboTsfS=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2OE[zN{c,OjV7NEi2N\|M9N2F-
BAF3	M{C3UGZ2dmO2aX;uJIF{e2G7		NEn0fII4OiCq		MVzHTVUxKD1iMD6wNFA{KM7:TR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3	NHe3Z\|FHfW6ldHnvckBie3OjeR?=		NXPJV5E3PzJiaB?=		M2rkcmdKPTBiPTCwMlAxODNizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3	NXnBUnN1TnWwY4Tpc44h[XO\|YYm=		NIHvOYw4OiCq		MV\HTVUxKD1iMD6wNFEh\|ryP	NUm4O5pbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
HCC827	NXezSmRsTnWwY4Tpc44h[XO\|YYm=		NWHvSIFXPzJiaB?=		NV7FTYR6T0l3MDC9JFAvODBzIN88US=>	Moi0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
PC9	M2K0fmZ2dmO2aX;uJIF{e2G7		M3Xkc\|czKGh?		M2n1UmdKPTBiPTCwMlAxOiEQvF2=	NIfue2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3	NUnrN5pTTnWwY4Tpc44h[XO\|YYm=		NEjLOIk1KGh?		MXnFR\|UxKD1iMD6wNFIh\|ryP	NHWz[oQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827	MXfGeY5kfGmxbjDhd5NigQ>?		NVzS[WNjOyCq		NHG4eoVKSzVyIE2gNE4xODJ3IN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR\|M{iyPUc,Ojd2M{O4Nlk9N2F-
H1975	Ml;KSpVv[3Srb36gZZN{[Xl?		M4fHUFMhcA>?		M1HhdmlEPTBiPTCwMlAxOjVizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR\|M{iyPUc,Ojd2M{O4Nlk9N2F-
H3255	MXzGeY5kfGmxbjDhd5NigQ>?		MWezJIg>		NVrTT4ZCUUN3MDC9JFAvODB2MTFOwG0>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR\|M{iyPUc,Ojd2M{O4Nlk9N2F-
NCI-H1975	NGjnUpNHfW6ldHnvckBie3OjeR?=		MknUO\|IhcA>?		NW\I[IFlT0l3MDC9JFAvODB3IN88US=>	NFLnTGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
PC9	MmH2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NXH0dJlKPzJiaB?=		NV7V[Gw6UUN3MDC9JFAvODB4NTFOwG0>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
NCI-H1975	MXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NU\pZo45PzJiaB?=		Ml\CTWM2OCB;IECuNFExPSEQvF2=	NXXTN2hzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVY3PDFpPkK4O\|E3PjRzPD;hQi=>
Sf21	M2PKOmZ2dmO2aX;uJIF{e2G7				NH;TVlRKSzVyIE2gNE4xOTJizszN	M{DITlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm2NlY4Lz5{N{m5OlI3PzxxYU6=
PC9-DRH	M1XSNmZ2dmO2aX;uJIF{e2G7		NVvLUWRYOiCq		NGfreYFKSzVyIE2gNE4xOTNizszN	NETST2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
BAF3	MnXKSpVv[3Srb36gZZN{[Xl?		NYTMc2h6PzJiaB?=		NWPvPZBNT0l3MDC9JFAvODF\|IN88US=>	M325VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827	NGL1b49HfW6ldHnvckBie3OjeR?=		NYDDR2hzQTZiaB?=		MWXFR\|UxKD1iMD6wNVQh\|ryP	NFewcmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEKyOVI3QSd-MkiyNlUzPjl:L3G+
HCC827	M2\6V2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NGrRb4w6PiCq		NFu5VWVGSzVyIE2gNE4xOTRizszN	NXjZ[FdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
NCI-H1975	NVW2fnVmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NXfjSFJsQTZiaB?=		M134WWVEPTBiPTCwMlAyPCEQvF2=	NIftVXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
NCI-H1975	NXH3Rmg2TnWwY4Tpc44h[XO\|YYm=		MWiyJIg>		NHf5SVJKSzVyIE2gNE4xOTVizszN	M1zWSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
H1975	M163SGZ2dmO2aX;uJIF{e2G7		NIjITYkzKGh?		NITscWVKSzVyIE2gNE4xOTVizszN	M{HrTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OU[4NlU{Lz5{Nkm2PFI2OzxxYU6=
PC9	MXfGeY5kfGmxbjDhd5NigQ>?		NFTZcGUzKGh?		NGrrcmdKSzVyIE2gNE4xOTdizszN	NVTKT\|ZQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OlgzPTNpPkK2PVY5OjV\|PD;hQi=>
NCI-H1975	M4fJfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NWLhc2ZSPzJiaB?=		NHnQPJlKSzVyIE2gNE4xOTlizszN	NIfETng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
NCI-H1975	Mn7hSpVv[3Srb36gZZN{[Xl?		MYW5OkBp		NUL0cVU6TUN3MDC9JFAvODF7IN88US=>	NEDreHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEKyOVI3QSd-MkiyNlUzPjl:L3G+
NCI-H1975	MlrmRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MoPWPVYhcA>?		NULTOJo3TUN3MDC9JFAvODF7IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZyM{m5NUc,Ojh4MEO5PVE9N2F-
NCI-H1975	NIe4XoFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NVnvR5lmPzJiaB?=		MW\JR\|UxKD1iMD6wNVkh\|ryP	M3rSS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEWzN\|QxLz5{OUi1N\|M1ODxxYU6=
HCC827	M1WzZmZ2dmO2aX;uJIF{e2G7		M{L0UVIhcA>?		M4\2emlEPTBiPTCwMlAzOyEQvF2=	NXviUpl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
NCI-H1975	MnW0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MXS3NkBp		Mkm1TWM2OCB;IECuNFI{KM7:TR?=	NUHDOY1jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
PC9	NYfNO2hUS3m2b4TvfIlkcXS7IHHzd4F6		NFq0ZWM4OiCq		NXnIPHZwT0l3MDC9JFAvODJ\|IN88US=>	NH\5PXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
NCI-H1975	M1rsUmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NUXwe3FFPzJiaB?=		NIDHTGZIUTVyIE2gNE4xOjRizszN	M2XmNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
HCC827	MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NW\pVFJ3PzJiaB?=		MU\JR\|UxKD1iMD6wNlU1KM7:TR?=	NYPzNpFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1O\|YzPzJpPkK5OVc3Ojd{PD;hQi=>
HCC827	MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MoDEO\|IhcA>?		NUTsVpRJUUN3MDC9JFAvODJ5IN88US=>	MlHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O\|MoRjJ7NE[2O\|c{RC:jPh?=
HCC827	NUjpbWFDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M{S0[lczKGh?		MUjJR\|UxKD1iMD6wNlch\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3M{O0NEc,Ojl6NUOzOFA9N2F-
NCI-H1975	M4\ldmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MX:3NkBp		M3jv[mlEPTBiPTCwMlA{KM7:TR?=	NF7VZlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECzN\|U4QSd-MkiwN\|M2Pzl:L3G+
H3255	M4fjdGZ2dmO2aX;uJIF{e2G7		NFXnTow4OiCq		MVHHTVUxKD1iMD6wN\|Mh\|ryP	M4fT[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H3255	NWHpV25FTnWwY4Tpc44h[XO\|YYm=		NUDiXYVHOiCq		NFLxU\|FKSzVyIE2gNE4xOzZizszN	NUnle2w1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O\|U3OjJ{PD;hQi=>
NCI-H1975	M3rLemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MU[3NkBp		MV\JR\|UxKD1iMD6wOFEh\|ryP	NF7lSWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUezNFE6Oid-Mkm3N\|AyQTJ:L3G+
NCI-H1975	NU\oSXZOTnWwY4Tpc44h[XO\|YYm=		MoLHNUBp		MnPZTWM2OCB;IECuNFQyKM7:TR?=	NWDXdW9xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
BAF3	NHTqOppHfW6ldHnvckBie3OjeR?=		MXi0JIg>		M1LxT2VEPTBiPTCwMlA1OyEQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975	MmezRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MnjkO\|IhcA>?		MmT6TWM2OCB;IECuNFQ4OiEQvF2=	NXGxfY5kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1O\|YzPzJpPkK5OVc3Ojd{PD;hQi=>
NCI-H1975	MmLHRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M1m2T\|czKGh?		M3PMSWlEPTBiPTCwMlA2OiEQvF2=	M3rUNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxOlM6Lz5{N{GzNVY{QTxxYU6=
PC9	M{HN[mZ2dmO2aX;uJIF{e2G7		MlfnNkBp		NWnqUWg6UUN3MDC9JFAvODV4IN88US=>	M4C0eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
NCI-H1975	Ml\TR5l1d3SxeHnjbZR6KGG\|c3H5		MXS3NkBp		NFHicGJKSzVyIE2gNE4xPiEQvF2=	NXPIRY5iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTNpPkK5OFg3QTV\|PD;hQi=>
HCC827	M36wPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7				NH3HOnVKSzVyIE2gNE4xPjF4IN88US=>	NIH6dGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
NCI-H1975	M2roTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7				MofzTWM2OCB;IECuNFY4KM7:TR?=	NV7zbZlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
HaCaT	M4\HdmZ2dmO2aX;uJIF{e2G7		NUPPdFE6OyCq		MljCTWM2OCB;IECuNFc{PyEQvF2=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR\|M{iyPUc,Ojd2M{O4Nlk9N2F-
NCI-H1975	M3jrcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MVy3NkBp		MnO3TWM2OCB;IECuNVMh\|ryP	M1e3UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5\|MESyPVk2PjxxYU6=
A431	M2fSdmZ2dmO2aX;uJIF{e2G7		NUD2cZQzOSCq		MVzJR\|UxKD1iMD6xOFEh\|ryP	NVzpd\|MzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1N\|Q6OjZpPkK5OVM1QTJ4PD;hQi=>
A549	MW\GeY5kfGmxbjDhd5NigQ>?				Mn3BTWM2OCB;IECuNVUh\|ryP	M1uxc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
Calu3	M{nVNGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NHjJR3Y4OiCq		NYLvcIVbT0l3MDC9JFAvOjZ2IN88US=>	NInsVVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
Sf9	MX\GeY5kfGmxbjDhd5NigQ>?		NXnrfXpVOjBibXnudy=>		M1vZfGlEPTBiPTCwMlI4QCEQvF2=	NVHrNpZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0PFIyPTFpPkK4OFgzOTVzPD;hQi=>
BAF3	MXjGeY5kfGmxbjDhd5NigQ>?		NVHsR\|hSPzJiaB?=		Mkm3S2k2OCB;IECuN{DPxE1?	NWS2UIxVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	MVrGeY5kfGmxbjDhd5NigQ>?		NF;Sd244OiCq		MkfXS2k2OCB;IECuN\|Eh\|ryP	M{[0cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H460	NGfnWW1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NWrNUJVCPzJiaB?=		NVzPSZk{UUN3MDC9JFAvPDF3OTFOwG0>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
LoVo	M{HqSWZ2dmO2aX;uJIF{e2G7		M3LxV\|IhcA>?		MlfpTWM2OCB;IECuOFgh\|ryP	NWTt[ZJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OlgzPTNpPkK2PVY5OjV\|PD;hQi=>
LoVo	NH33XJZHfW6ldHnvckBie3OjeR?=		Moi1NkBp		MYDJR\|UxKD1iMD60PEDPxE1?	MmPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OU[yOlcoRjJ5OUm2NlY4RC:jPh?=
A549	NGXr[JNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NWnRNFloPzJiaB?=		NIXWOHZKSzVyIE2gNE41QDZizszN	M2LrflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
BAF3	NVKwWpFQTnWwY4Tpc44h[XO\|YYm=		NV;zdZRyPzJiaB?=		MonKS2k2OCB;IECuOUDPxE1?	M4\GZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A549	Mm\GRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M3vwbVczKGh?		NIfqRYhKSzVyIE2gNE42OyEQvF2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR4Nke3N{c,Ojl2Nk[3O\|M9N2F-
A549	MYHDfZRwfG:6aXPpeJkh[XO\|YYm=		NHTlW4I4OiCq		NGWxSY9KSzVyIE2gNE42OyEQvF2=	MlLzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN\|QxRC:jPh?=
BAF3	MmnHSpVv[3Srb36gZZN{[Xl?		MYm3NkBp		NHzjSZpIUTVyIE2gNE42PSEQvF2=	NXLxVnVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3	Mmj1SpVv[3Srb36gZZN{[Xl?		MUS3NkBp		NVvMTG9CT0l3MDC9JFAvPTZizszN	M{PJT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HEK293	NV[1T5JsTnWwY4Tpc44h[XO\|YYm=				NX72PFFbUUN3MDC9JFAvPTdizszN	MoWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
BAF3	M1Hoc2Z2dmO2aX;uJIF{e2G7		M2jtc\|czKGh?		MmLzS2k2OCB;IECuOVkh\|ryP	NWrlR4VMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
A431	MkTGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?				Mk\yTWM2OCB;IECuOlE2PiEQvF2=	NUS3RYZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
HT-29	NVviUoFNS3m2b4TvfIlkcXS7IHHzd4F6		NHniUGU4OiCq		MUHJR\|UxKD1iMD62OUDPxE1?	Mor6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVMoRjJ7NEi2PVU{RC:jPh?=
A431	NH:0eWVHfW6ldHnvckBie3OjeR?=		MnTUPVYhcA>?		NI[4OHpGSzVyIE2gNE43PjdizszN	M3HuOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkK1NlY6Lz5{OEKyOVI3QTxxYU6=
A431	M4rUUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		Mn\LPVYhcA>?		MkfpSWM2OCB;IECuOlch\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
A431	NH3YWnlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MnP6O\|IhcA>?		NYfYXW9WUUN3MDC9JFAvPjh3IN88US=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV\|NEmyOkc,Ojl3M{S5NlY9N2F-
A431	MlnDRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NXXmSYl5QTZiaB?=		MYDFR\|UxKD1iMD63JO69VQ>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZyM{m5NUc,Ojh4MEO5PVE9N2F-
A549	MnHsR5l1d3SxeHnjbZR6KGG\|c3H5		NFrnelk4OiCq		MlW4TWM2OCB;IECuPFch\|ryP	NEPPU\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS4Olk2Oyd-Mkm0PFY6PTN:L3G+
A431	M3TaTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MWS3NkBp		NFHpVVZKSzVyIE2gNE45QTNizszN	MmTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{G2N\|koRjJ5MUOxOlM6RC:jPh?=
BA/F3	NUPVbo9TSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		M3ezV\|czKGh?		NVPnWGFrUUN3MDC9JFEh\|ryP	NFvCR\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK1PFUzOSd-Mk[yOVg2OjF:L3G+
BAF3	NGfQVXNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVPBcWlOPzJiaB?=		NVOxd5VST0l3MDC9JFEvOiEQvF2=	NIrwfWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
NCI-H2122	NFWwT5VHfW6ldHnvckBie3OjeR?=		NUXGephrPzJiaB?=		M3f0XmdKPTBiPTCxMlIh\|ryP	NFfXN3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
A431	MoCzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MkC1O\|IhcA>?		MnvZTWM2OCB;IEGuNlQh\|ryP	MkezQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
A431	NXn3W5dUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NXzDbpNsPzJiaB?=		Mn;LTWM2OCB;IEGuNlYh\|ryP	NUfhcG9SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N\|AyQTJpPkK5O\|MxOTl{PD;hQi=>
A431	Mlv3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NWXRc4dzPzJiaB?=		Mk\ZTWM2OCB;IEGuOlA1KM7:TR?=	M{DvU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEOzOVc6Lz5{OECzN\|U4QTxxYU6=
A549	M37HfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MWG5OkBp		MVjFR\|UxKD1iMT64N{DPxE1?	NGnn[Is9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
CHL	NUWyNHZCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXO3NkBp		NWnBWJk3T0l3MDC9JFIvQSEQvF2=	NULFTIZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
H1355	NFTVb41HfW6ldHnvckBie3OjeR?=		MlThO\|IhcA>?		MYjHTVUxKD1iMzFOwG0>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
H1703	MkjqSpVv[3Srb36gZZN{[Xl?		M1jxe\|czKGh?		NGXrOlNIUTVyIE2gN{42KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
A549	MUfGeY5kfGmxbjDhd5NigQ>?		NIrIXow4OiCq		M{\p[2dKPTBiPTCzMlUh\|ryP	NF;afWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
CHO	M2LEUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVy3NkBp		NF3IPI1IUTVyIE2gOE4zKM7:TR?=	NF3mXVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3	NVXPb2N1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NYe4RVQ2PzJiaB?=		MlrJTWM2OCB;IESuOlEh\|ryP	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
BAF3	M4O1WWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NVzycWRFPzJiaB?=		NUn0OIN1UUN3MDC9JFUvOTVizszN	MkXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
BEAS2B	NYXveJhrSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NEnITJo4OiCq		NX3ub45JUUN3MDC9JFE1NjlizszN	NVPhRnNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVY3PDFpPkK4O\|E3PjRzPD;hQi=>
NCI-H1975	MkDQSpVv[3Srb36gZZN{[Xl?		NETBfFEzKGh?		MoPnTWM2OCB;IEG1JO69VQ>?	NWj5dHA6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
PC9	NHLnOZRHfW6ldHnvckBie3OjeR?=		MojRNkBp		NY\YXVlYUUN3MDC9JFE4KM7:TR?=	MnflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
LoVo	NUTINoxnTnWwY4Tpc44h[XO\|YYm=		MVGyJIg>		NYLlOodyUUN3MDC9JFQ5OCEQvF2=	NWTUVGJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
NCI-H1975	MXnBcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl?				NEDaUmFCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFk4OE1iZH;1ZoxmKG23dHHueEB5\W6xZ4Lh[pRm\CCrbjDTR2lFKG2xdYPlJIF{e2W\|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDJwNTDt[{9s\y:mYYmsJJBwKHGmIH\vdkA4KGSjeYOgdoVt[XSrdnWgeI8h[2:wdILvcC=>	Ml3nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
rat hepatocytes	MYrGeY5kfGmxbjDhd5NigQ>?				MnXnTY51emmwc3njJINt\WG{YX7j[UBqdiC{YYSgbIVx[XSxY4n0[ZMhdWWjc4Xy[YQheGW{IEGwK\|Yh[2WubIO=	NILncm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO\|E6PjN:L3G+
human hepatocytes	M3;KSWZ2dmO2aX;uJIF{e2G7				M2LVXmlvfHKrboPpZ{BkdGWjcnHuZ4UhcW5iaIXtZY4hcGWyYYTvZ5l1\XNibXXhd5Vz\WRicHXyJFExLzZiY3XscJM>	NVjWTml{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
NCI-H1975	Mkn6RY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				NW\NOpM1SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q6PzCPIHTveYJt\SCvdYThcpQhgGWwb3fyZYZ1\WRiaX6gV2NKTCCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCB3IH3nM4toN2SjeTygdI8heWRiZn;yJFch\GG7czDy[YxifGm4ZTD0c{Bkd262cn;s	NX3MfnR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO\|E6PjNpPkK1NlcyQTZ\|PD;hQi=>
NCI-H1975	M3[0ZWZ2dmO2aX;uJIF{e2G7				MnrVV4Vt\WO2aY\peJkhcW6mZYisJJJifGmxIH;mJGlEPTBiZn;yJGVITlJiVEe5NG0wVDh3OGKg[I92[mynIH31eIFvfCCneIDy[ZN{cW6pIHj1cYFvKE6FST3INVk4PSClZXzsd{B1dyCLQ{WwJIZweiC5aXzkJJR6eGViRVfGVkBmgHC{ZYPzbY5oKGi3bXHuJGE1OzFiY3XscJM>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd\|MEG5Nkc,Ojl5M{CxPVI9N2F-
NCI-H1975	NYLXSYVFSW62aYT1cY9zKGGldHn2bZR6KGG\|c3H5				M{\OWGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGVITlJiVEe5NG0wVDh3OGKg[I92[mynIH31eIFvfCCneIDy[ZN{cW6pIHj1cYFvKE6FST3INVk4PSClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDCRWxDN2NiYYTofY1q[yCwdXTlJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFExKG2pL3vnMEBxdyCkaXSg[o9zKDJzIHThfZM>	M{TnUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{OwNVkzLz5{OUezNFE6OjxxYU6=
HCC827	NF7aWW9CeG:ydH;zbZMh[XO\|YYm=				NEHUO5dKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjDR\|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO\|Q3NUF5NUCg[IVt\XSrb36gcZV1[W62IHHzd4V{e2WmIHHzJIViemy7IHHwc5B1d3SrYzDj[YxteyCjdDCzJJVOKGGodHXyJFI1KGi{czDifUBCdm6neHnuJHYuTkmWQz;wdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKG[ub4egZ5l1d22ndIL5JEhTfmJiPTCxMlM1LSl?	NFmzOms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
HCC827	M2DQWGFxd3C2b4Ppd{Bie3OjeR?=				NG\MNZRKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjDR\|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO\|Q3NUF5NUCg[IVt\XSrb36gcZV1[W62IHHzd4V{e2WmIHHzJIxifGViYYDvdJRwfGmlIHPlcIx{KGG2IEOgeW0h[W[2ZYKgNlQhcHK\|IHL5JGFvdmW6aX6gWk1HUVSFL4Dyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2comgLHJ3[iB;IEK3MlE1LSl?	MoDPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O\|MoRjJ7NE[2O\|c{RC:jPh?=
A549	MUTGeY5kfGmxbjDhd5NigQ>?				NWflfVVSW2WuZXP0bZZqfHlicnH0bY8hd2ZiSVO1NEBnd3JiaIXtZY4hSTV2OTDj[YxteyCneIDy[ZN{cW6pIIfpcIQufHmyZTDFS2ZTN0tvUnHzJI12fGGwdDD0c{BKSzVyIH\vdkBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQ>	Ml7LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVMoRjJ7NEi2PVU{RC:jPh?=
HCC827	MlTBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MXq3NkBp		NUjLXYViSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR2M5OjdiY3XscJMh[XRiMTD1UUBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5JJJmdGG2aY\lJJRwKGOxboTyc4w>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV5NkK3Nkc,Ojl3N{[yO\|I9N2F-
BAF3	M3HsfmZ2dmO2aX;uJIF{e2G7		NFLCblIzKGh?		MkLtTY5pcWKrdHnvckBw\iCHR1\SJHQ4QTCPL1y4OVhTN0N5OUfTJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRWY{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDFS2YucW6mdXPl[EBz\WOncITvdkBxcG:\|cHjvdplt[XSrb36gZZQhOSC2bzCzJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhTUeIIIP0bY12dGG2aX;uJIZweiBzNTDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
BAF3	M13QfWZ2dmO2aX;uJIF{e2G7		MYSyJIg>		NIT5dVRKdmirYnn0bY9vKG:oIFXHSnIhOTmGL2S3PVBON0N5OUfTJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCRWY{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDFS2YucW6mdXPl[EBz\WOncITvdkBxcG:\|cHjvdplt[XSrb36gZZQhOSC2bzCzJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhTUeIIIP0bY12dGG2aX;uJIZweiBzNTDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
NCI-H1975	MkHyRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7				NVTPOYx3SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IIjlco9oemGodHXkJIlvKFOWT1PLMWZwgG5zboWvUop2KG63ZHWgcY92e2ViYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC2dX3vdkBoem:5dHigZZQhOjBibXevb4cw\GG7LDDwc{By\CCob4KgNVQh\GG7czDy[YxifGm4ZTD0c{B2dnS{ZXH0[YQh[2:wdILvcC=>	NEXhVXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO5OVIyQSd-MkizPVUzOTl:L3G+
Caco2	NEDBSndHfW6ldHnvckBie3OjeR?=		Mk\JNkBp		NX\kWpdWTW[obIX4JJJifGmxIH;mJIFxeGG{ZX70JJBmem2nYXLpcIl1gSCocn;tJIJie2:uYYTldoFtKHOrZHWgeI8h[XCrY3HsJJNq\GVib4\ldkBieGmlYXygd4ll\SC2bzDiZZNwdGG2ZYLhcEB{cWSnIH;2[ZIhcW5iaIXtZY4hS2Glb{KgZ4VtdHNiYYSgOUB2VSCrbnP1ZoF1\WRiZn;yJFIhcHK\|	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
A431	NXLPOZZRTnWwY4Tpc44h[XO\|YYm=				MYnT[Yxm[3Srdnn0fUBz[XSrbzDv[kBGSzVyIH\vdkBpfW2jbjDBOFMyKGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEWJRmKgeI8hTUN3MDDmc5IhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTNUx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQ>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O\|U9N2F-
Caco2	NEGyXoNHfW6ldHnvckBie3OjeR?=		NIDTVmYzKGh?		NVvJdpBtSXCyYYLlcpQheGW{bXXhZoltcXS7IHHjdo9{eyCjcHnjZYwhfG9iYnHzc4xifGW{YXygd4ll\SCrbjDoeY1idiCFYXPvNkBk\WyuczDheEA2KHWPIHnuZ5Vj[XSnZDDmc5IhOiCqcoO=	NX7IXGNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
Caco2	Ml7uSpVv[3Srb36gZZN{[Xl?		MoP1NkBp		NY\2UGFRSXCyYYLlcpQheGW{bXXhZoltcXS7IHHjdo9{eyCkYYPvcIF1\XKjbDD0c{BieGmlYXygd4ll\SCrbjDoeY1idiCFYXPvNkBk\WyuczDheEA2KHWPIHnuZ5Vj[XSnZDDmc5IhOiCqcoO=	MmOyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
NCI-H1975	MnnzSpVv[3Srb36gZZN{[Xl?		NFnyT\|A1KGh?		MYDJcohq[mm2aX;uJI9nKEWJRmKgUFg2QFJxVEe5NG0hdXW2YX70JIlvKGi3bXHuJG5EUS2KMUm3OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iQXv0JJBpd3OyaH;yfYxifGmxbjDheEBVcHJ\|MEivV4VzPDd\|IIPpeIUh[XRiMTD1UUBu\WG\|dYLl[EBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827	M3zKPGZ2dmO2aX;uJIF{e2G7		MmrhOEBp		NFq2WXlKdmirYnn0bY9vKG:oIFXHSnIh\XixbjCxPUBl\WyndHnvckBufXSjboSgbY4hcHWvYX6gTGNEQDJ5IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBCc3RicHjvd5Bpd3K7bHH0bY9vKGG2IGTodlMxQC:VZYK0O\|Mhe2m2ZTDheEAyKHWPIH3lZZN2emWmIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	M4XKRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975	MonTRZBweHSxc3nzJIF{e2G7		MljxOFghcA>?		NUm3bHJLUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51KGG\|c3Xzd4VlKGG\|IHPhd5Bie2V\|IHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827	MVLBdI9xfG:\|aYOgZZN{[Xl?		M{TON\|Q5KGh?		M{LaOmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIHX4c44hOTliZHXs[ZRqd25ibYX0ZY51KGG\|c3Xzd4VlKGG\|IHPhd5Bie2VvMzDjcIVifmGpZTDheEAyKHWPIHHmeIVzKDR6IHjyd{BjgSCrbX31co9jdG:2dHnu[y=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
PC9	NH\POoZCeG:ydH;zbZMh[XO\|YYm=		M3OyS\|Q5KGh?		M2PVZmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iUFO5JINmdGy\|IHjhdoJwemmwZzDFS2ZTKGW6b36gNVkh\GWuZYTpc44hdXW2YX70JIF{e2W\|c3XkJIF{KGOjc4Dhd4UuOyClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?=	NUPNW2g5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
H3255	MYPBdI9xfG:\|aYOgZZN{[Xl?		MYq0PEBp		NEnzVZZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFizNlU2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTKG23dHHueEBie3Onc4Pl[EBieyClYYPwZZNmNTNiY3zlZZZi\2ViYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbne=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975	MXjBdI9xfG:\|aYOgZZN{[Xl?		NYnUOXhQPDhiaB?=		NFH3O\|lKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UO\|kxVSCvdYThcpQh[XO\|ZYPz[YQh[XNiUFHSVEBkdGWjdnHn[UBifCBzIIXNJIFnfGW{IES4JIhzeyCkeTDpcY12dm:kbH;0eIlv\w>?	MorkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
PC9	NV;TUWxvSXCxcITvd4l{KGG\|c3H5		M3;qdVQ5KGh?		NEDLN5hKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIGDDPUBk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o	M4nkdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827	MnHMRZBweHSxc3nzJIF{e2G7		MkK3OFghcA>?		NWThW5o{UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIR2M5OjdiY3XscJMhcGG{Yn;ybY5oKEWJRmKg[ZhwdiBzOTDk[YxmfGmxbjDteZRidnRiYYPz[ZN{\WRiYYOgVGFTWCClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?=	NVLKdXFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
H3255	NHP0PJlCeG:ydH;zbZMh[XO\|YYm=		NI\J[FI1QCCq		MXnJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEh\|MkW1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSJI12fGGwdDDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[WenIHH0JFEhfU1iYX\0[ZIhPDhiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n	NY\MdHhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H1975	NXnJWWJGTnWwY4Tpc44h[XO\|YYm=				MlnMV4Vt\WO2aY\peJkhemG2aX:gc4YhUUN3MDDmc5IhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQhfG9iSVO1NEBnd3JiaIXtZY4hSTR\|MTDj[YxteyCqYYLic5Jqdmdid3ns[E11gXCnIFXHSnI>	M4\RbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
human hepatocytes	MVHGeY5kfGmxbjDhd5NigQ>?				Mkf3TY51emmwc3njJINt\WG{YX7j[UBqdiCqdX3hckBp\XCjdH;jfZRmeyCjc4Pld5Nm\CCyZYKgcYltdGmxbjDj[Yxtew>?	NHfjS4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
rat hepatocytes	MXTGeY5kfGmxbjDhd5NigQ>?				M3iy[2lvfHKrboPpZ{BkdGWjcnHuZ4UhcW5icnH0JIhmeGG2b3P5eIV{KGG\|c3Xzd4VlKHCncjDtbYxtcW:wIHPlcIx{	M{XkXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEK2PVk3Lz5{OESyOlk6PjxxYU6=
A549, NCI-H1975	NVPROHZuTnWwY4Tpc44h[XO\|YYm=				M17YSXNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKEWJRj3zeIlufWyjdHXkJJdqdGRidInw[UBGT0[UIHnuJIh2dWGwIFG1OFkh[2WubIOgeI8hUUN3MDDmc5IhTUeIUjDMPFU5Wi:WN{mwUUBld3WkbHWgcZV1[W62IHnuJIh2dWGwIF7DTU1JOTl5NTDj[Yxtew>?	MoXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
A549, PC9	NXf0VHBzTnWwY4Tpc44h[XO\|YYm=				Mnq0V4Vt\WO2aY\peJkhemG2aX:gc4YhUUN3MDDmc5IhTUeILYP0bY12dGG2ZXSge4lt\CC2eYDlJGVITlJiaX6gbJVu[W5iQUW0PUBk\WyuczD0c{BKSzVyIH\vdkBGT0[UIHTlcIV1cW:wIH31eIFvfCCrbjDoeY1idiCSQ{mgZ4VtdHN?	NF7LU2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
HCC827	MWXBdI9xfG:\|aYOgZZN{[Xl?				M37BeWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIFW3OFYhfG9iQUe1NEBl\WyndHnvckBufXSjboSgZZN{\XO\|ZXSgZZMh\WG{bImgZZBweHSxdHnjJINmdGy\|IHH0JFMhfU1iYX\0[ZIhOjRiaILzJIJ6KEGwbnX4bY4hXi2ISWTDM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dpkhMFK4YjC9JFEvOzRidH:gNU43PyVr	NIXHW4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi1N\|M1OCd-Mkm4OVM{PDB:L3G+
NCI-H1975	NFGwSZRHfW6ldHnvckBie3OjeR?=				MofKTY5pcWKrdHnvckBw\iCHR1\SJGw5PTiUL2S3PVBOKGSxdXLs[UBufXSjboSgdIhwe3Cqb4L5cIF1cW:wIHnuJGVITi2\|dHnteYxifGWmIHj1cYFvKE6FST3INVk4PSClZXzsd{BifCBzIITvJFExOCCwTTDifUBY\XO2ZYLuJIJtd3RibXX0bI9l	NWnCR5I6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5NFYyOTRpPkK5PVA3OTF2PD;hQi=>
A431	NWLPT5YyTnWwY4Tpc44h[XO\|YYm=				NEPMVIRU\WynY4Tpeol1gSC{YYTpc{whemG2aX:gTWM2OCCob4KgbJVu[W5iQUSzNUBk\WyuczDveoVz\XiycnXzd4lv\yC5aXzkMZR6eGViRVfGVkB1dyCLQ{WwJIZweiCqdX3hckBPS0lvSEG5O\|Uh[2WubIOg[ZhxemW\|c3nu[{BGT0[UIGS3PVBON0x6NUjSJI12fGGwdB?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MU[zPUc,OjdzM{G2N\|k9N2F-
PC9	M{Xs[WFvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?=				MkPLRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFO5JINmdGy\|IHjhdoJwemmwZzDFS2ZTKGW6b36gNVkh\GWuZYTpc44h[WO2aY\heIlv\yCvdYThcpQhgGWwb3fyZYZ1\WRiaX6gV2NKTCCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCBzMDDt[{9s\y:mYYmsJJBwKHGmIH\vdkA4KGSjeYOgdoVt[XSrdnWgeI8h[2:wdILvcC=>	Mn;3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
A431	M12yeGFvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?=				Mn7VRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUSzNUBk\WyuczD4[Y5w\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFUhdWdxa3ev[IF6NCCybzDx[EBnd3JiNzDkZZl{KHKnbHH0bZZmKHSxIHPvcpRzd2x?	M1uxWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	p-EGFR / p-AKT / p-ERK; PubMed: 28416483 Cancer Res PC-9/BRc1 cells were treated with the indicated doses of osimertinib. Drugs were refreshed every 24 hours. Cellular lysates were probed with the indicated antibodies. Osim: osimertinib. ABCB1; PubMed: 27649127 Molecules The effect of osimertinib at 0.3 μM on the expression of ABCB1 was measured in KB-3-1 and KB-C2 cell lines for 0, 24, 48, and 72 h.	28416483 27649127
Growth inhibition assay	Cell viability; PubMed: 31043587 Cell Death Dis Cells were treated with gefitinib or osimertinib for 72 h. Cell viability was measured by MTT assay. P < 0.05, P < 0.01, **P < 0.005 by t-test.	31043587
Immunofluorescence	Ki67 / γH2AX / p16; PubMed: 29212784 EMBO Mol Med PC9ER cells were treated for 5 days with either 3×mAbs (20 μg/ml), saline (CTRL), or with a low dose of osimertinib (2.5 nM). Shown are representative images of cells fixed in paraformaldehyde and immunostained for KI67 (panel E), γH2AX (panel F), and p16 (panel G). DAPI counterstaining was used to follow nuclear localization. Scale bar, 20 μm. The box and whisker plots, where the ends of the box are the upper and lower quartiles, depict quantifications of results obtained in three independent experiments. P ≤ 0.01, *P ≤ 0.001, n = 4; one-way ANOVA with Tukey's test.	29212784

体内試験

AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. ^[2]

お薦めの試験操作（参考用のみ）

動物試験： ^[2]	- 合併動物モデル： Mice bearing PC9 and H1975 xenograft tumors 投薬量： ~5 mg/kg 投与方法： p.o. (参考用のみ)

参考

溶解度 (25°C)

体外	DMSO	99 mg/mL (198.15 mM) warming
	Water	Insoluble
	Ethanol	'43 mg/mL warmed '43
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O 混合させたのち直ちに使用することを推奨します。	7.5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Osimertinib (AZD9291) SDFをダウンロードする

分子量	499.61
化学式	C₂₈ H₃₃ N₇ O₂
CAS No.	1421373-65-0
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	Mereletinib
Smiles	CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02841579	Completed	Drug: Osimertinib	Non-Small Cell Lung Cancer	MedSIR\|AstraZeneca	August 2016	Phase 2
NCT02771314	Unknown status	Drug: AZD9291	Non Small Cell Lung Cancer	Hellenic Oncology Research Group	August 2 2016	Phase 2
NCT02529995	Completed	Drug: AZD9291 40 mg\|Drug: AZD9291 80 mg	Carcinoma Non-Small-Cell Lung With EGFR Mutation Positive	AstraZeneca	August 24 2015	Phase 1
NCT02491944	Completed	Drug: AZD9291\|Drug: [14C]AZD9291	Oncology	AstraZeneca	July 2015	Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須
*大学・企業名:
*名前:
*電子メール:
*電話番号:
*内容:

よくある質問（FAQ）

質問1：
Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?
回答：
Osimertinib can be used for animal study. The vehicle we suggest is: 1% DMSO+30% PEG 300+dd H2O at up to 30mg/ml.

EGFRシグナル伝達経路

相関EGFR製品

Erlotinib (OSI-774)

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B)

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Lapatinib (GW-572016)

Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.

研究分野別

製品類型

Osimertinib (AZD9291)

文献中Selleckの製品使用例(253)

製品安全説明書

EGFR阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Osimertinib (AZD9291) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2021-09-06)

技術サポート

よくある質問（FAQ）

EGFRシグナル伝達経路

相関EGFR製品